Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Andrew Demidowich

Hospitalist Bethesda, MD Medical Doctor

NPI 1144489717 CMS profile 1276126

8600 Old Georgetown Rd, Bethesda, MD 20814

Open in the dashboard

General payments

$557

7 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$21,571 paid to institutions, not to them · program years 2022–2023

Through program year 2025, Andrew Demidowich of Bethesda, MD is reported in the CMS Open Payments database as having received $557 across 7 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $21,571 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $490 6
2023 General $67 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Demidowich
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Andrew Demidowich were reported at $490. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Andrew Demidowich Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $0 $85 $27–$174 $149
2023 $67 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $490 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Abbott Laboratories $205 3 payments
  2. Beta Bionics, Inc. $102 1 payment
  3. Amgen Inc. $98 1 payment
  4. Novo Nordisk Inc $94 1 payment
  5. Corcept Therapeutics $58 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $499 6 payments
  2. Education $58 1 payment
Products named General payments · program years 2023–2025
  1. FreeStyle Libre 3 $205 3 payments
  2. iLet Bionic Pancreas Automated insulin delivery system $102 1 payment
  3. iLet Bionic Pancreas Automated insulin delivery system $102 1 payment
  4. iLet Bionic Pancreas Automated insulin delivery system $102 1 payment
  5. iLet Insulin Infusion Kit Inset $102 1 payment
  6. iLet Insulin Infusion Kit Contact Detach $102 1 payment
  7. TAVNEOS $98 1 payment
  8. Korlym $58 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

45

Median for Hospitalist: 109

Drug cost

$8,575

Median for Hospitalist: $6,399

Branded share of claims

100%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gvoke Hypopen 2-Pack Glucagon Brand 12 $7,375
Nano 2nd Gen Pen Needle Pen Needle, Diabetic Brand 19 $1,023
Metformin Hcl Er Metformin Hcl Brand 14 $178

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$65,945

Medicare's payments for the services billed

Medicare patients

306

Average age 74

Services billed

739

168 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 65%
Arthritis 50%
Heart failure 48%
Depression 47%
Ischemic heart disease 45%
Atrial fibrillation 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record